Literature DB >> 15568191

The application of enhanced parallel gatekeeping strategies.

Xun Chen1, Xiaohui Luo, Tom Capizzi.   

Abstract

The parallel gatekeeping strategy proposed by Dmitrienko et al. (Statist. Med. 2003; 22:2387-2400) provides a flexible framework for the pursuit of strong control on study wise type I error rate. This paper further explores the application of the weighted Simes parallel gatekeeping procedure recommended by Dmitrienko et al. and proposes some modifications to it to better incorporate the interrelationships of different hypotheses in actual clinical trials and to achieve better power performance. We first propose a simple method to quantitatively control the impact of secondary tests on the testing of primary hypotheses. We then introduce a matched gatekeeping procedure to exemplify how to address special relationships between individual primary and secondary tests following the parallel gatekeeping framework. Our simulation study demonstrates that the enhanced gatekeeping procedures generally result in more powerful tests than the parallel gatekeeping procedure in Dmitrienko et al. whenever applicable. Copyright 2004 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2005        PMID: 15568191     DOI: 10.1002/sim.2005

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests.

Authors:  Frank Bretz; Martin Posch; Ekkehard Glimm; Florian Klinglmueller; Willi Maurer; Kornelius Rohmeyer
Journal:  Biom J       Date:  2011-08-12       Impact factor: 2.207

2.  Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Willie R Earley; Hua Guo; György Németh; Judit Harsányi; Michael E Thase
Journal:  Psychopharmacol Bull       Date:  2018-06-20

3.  A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder.

Authors:  Carl Gommoll; Suresh Durgam; Maju Mathews; Giovanna Forero; Rene Nunez; Xiongwen Tang; Michael E Thase
Journal:  Depress Anxiety       Date:  2015-04-17       Impact factor: 6.505

4.  Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Maju Mathews; Carl Gommoll; Dalei Chen; Rene Nunez; Arif Khan
Journal:  Int Clin Psychopharmacol       Date:  2015-03       Impact factor: 1.659

5.  Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study.

Authors:  Willie R Earley; Maria V Burgess; Barbara Khan; Ludmyla Rekeda; Trisha Suppes; Mauricio Tohen; Joseph R Calabrese
Journal:  Bipolar Disord       Date:  2019-11-06       Impact factor: 6.744

6.  A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder.

Authors:  Suresh Durgam; Changzheng Chen; Raffaele Migliore; Chandran Prakash; John Edwards; Robert L Findling
Journal:  Paediatr Drugs       Date:  2018-08       Impact factor: 3.022

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.